{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:48:48Z","timestamp":1782452928932,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immunotherapy has transformed the management of melanoma and is now a central component of care for patients with high\u2010risk, unresectable, and metastatic disease. Immune checkpoint inhibitors targeting programmed death 1 (PD\u20101), cytotoxic T\u2010lymphocyte\u2013associated antigen 4 (CTLA\u20104), and lymphocyte activation gene 3 (LAG\u20103) enhance antitumour immune responses and have resulted in substantial improvements in survival, with durable disease control in a proportion of patients. In Australia and New Zealand, immunotherapy is routinely used across the melanoma disease continuum, including neoadjuvant, adjuvant, and metastatic settings, supported by evolving regulatory approvals and funding pathways. This review summarises current immunotherapy approaches to melanoma, with a focus on how these therapies are used in routine Australian practice, including mechanisms of action, indications across disease stages, commonly used agents, special melanoma subtypes, benefits and limitations of treatment, immune\u2010related adverse events, particularly cutaneous toxicities, and emerging therapies. The role of dermatologists within multidisciplinary melanoma care is highlighted.<\/jats:p>","DOI":"10.1111\/ajd.70158","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:32:11Z","timestamp":1782451931000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy for Melanoma: A Concise Clinical Review for Australasian Practice"],"prefix":"10.1111","author":[{"given":"Alexandra","family":"Stacy","sequence":"first","affiliation":[{"name":"Liverpool Hospital  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Wynn","sequence":"additional","affiliation":[{"name":"Orange Health Service  Orange New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7491-7274","authenticated-orcid":false,"given":"Nicole","family":"Seebacher","sequence":"additional","affiliation":[{"name":"The Skin Hospital  Darlinghurst, Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_2_13_3_1","volume-title":"Mkin","author":"Cancer Australia","year":"2025"},{"key":"e_1_2_13_4_1","volume-title":"Skin Cancer Incidence and Mortality","author":"Cancer Council Australia","year":"2023"},{"issue":"4","key":"e_1_2_13_5_1","article-title":"Overall Survival and Response With Nivolumab and Relatlimab in Advanced Melanoma (RELATIVITY\u2010047)","volume":"2","author":"Long G. V.","year":"2023","journal-title":"New England Journal of Medicine Evidence"},{"key":"e_1_2_13_6_1","first-page":"1684","article-title":"Final, 10\u2010Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma (CheckMate 067)","volume":"391","author":"Wolchok J. D.","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02355"},{"key":"e_1_2_13_14_1","volume-title":"Nivolumab + Ipilimumab: Medicine Status (Stage III Melanoma Before Surgery)","author":"Pharmaceutical Benefits Scheme (PBS)","year":"2025"},{"key":"e_1_2_13_15_1","unstructured":"Australian Government Department of Health and Aged Care \u201cNew and Expanded PBS Listings\u2026 (Includes Nivolumab and Ipilimumab for Stage III Melanoma Before Surgery From 1 Aug 2025) \u201d(2025) published August 11 2025."},{"key":"e_1_2_13_16_1","unstructured":"Urological Society of Australia and New Zealand (USANZ) \u201cPBS Listings Implemented 1 August 2025 (PDF) \u201d(2025) published August 1 2025."},{"key":"e_1_2_13_17_1","volume-title":"Management of Immune\u2010Related Adverse Events (irAEs)","author":"eviQ Cancer Treatments Online"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2024.039"},{"key":"e_1_2_13_19_1","volume-title":"Side Effect and Toxicity Management: Immunological (irAEs Resources)","author":"eviQ Cancer Treatments Online"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_2_13_21_1","volume-title":"Melanoma Metastatic: Ipilimumab and Nivolumab (Induction)","author":"eviQ Cancer Treatments Online"},{"key":"e_1_2_13_22_1","volume-title":"AusPAR: Opdualag (Nivolumab\/Relatlimab)","author":"Therapeutic Goods Administration (TGA)","year":"2024"},{"key":"e_1_2_13_23_1","volume-title":"Melanoma Metastatic: Nivolumab\/Relatlimab","author":"eviQ Cancer Treatments Online"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061383"},{"key":"e_1_2_13_25_1","volume-title":"AusPAR: Talimogene Laherparepvec (Imlygic)","author":"Therapeutic Goods Administration (TGA)","year":"2016"},{"key":"e_1_2_13_26_1","volume-title":"AusPAR Attachment: Product Information for Imlygic (Talimogene Laherparepvec)","author":"Therapeutic Goods Administration (TGA)","year":"2016"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680407"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30258"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304753"},{"key":"e_1_2_13_31_1","volume-title":"AusPAR: Kimmtrak (Tebentafusp)","author":"Therapeutic Goods Administration (TGA)","year":"2022"},{"key":"e_1_2_13_32_1","volume-title":"Tebentafusp (Kimmtrak): PBS Item Listing","author":"Pharmaceutical Benefits Scheme (PBS)"},{"key":"e_1_2_13_33_1","volume-title":"Melanoma Metastatic (Uveal): Tebentafusp","author":"eviQ Cancer Treatments Online","year":"2025"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"e_1_2_13_35_1","first-page":"12","article-title":"Immune Checkpoint Inhibitor Therapy During Pregnancy: A Case Series and Systematic Review","volume":"181","author":"Gougis P.","year":"2023","journal-title":"European Journal of Cancer"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15811"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238591"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19750"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_2_13_40_1","article-title":"Cutaneous Adverse Events of Immune Checkpoint Inhibitors","volume":"11","author":"Apalla Z.","year":"2021","journal-title":"Dermatology Practical & Conceptual"},{"key":"e_1_2_13_41_1","volume-title":"Clinical Practice Guidelines for the Diagnosis and Management of Melanoma","author":"Cancer Council Australia"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.70158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:32:17Z","timestamp":1782451937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.70158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":39,"alternative-id":["10.1111\/ajd.70158"],"URL":"https:\/\/doi.org\/10.1111\/ajd.70158","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"2026-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajd.70158"}}